Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility

Cash runway extended through at least February 2023 based upon debt restructuring agreement with IPF Partners (IPF) and equity-linked financing facility for up to EUR 6 million with Iris Capital Investment (IRIS) Extended cash runway provides added flexibility to capitalize on upcoming Phase 2 DESTINY-1 results for PXL065 in NASH expected this quarter and independently … [Read more…]

BioDuro-Sundia and X-Chem Enter Partnership to Launch DEL Services in China for the Discovery of New Small Molecule Drugs

SHANGHAI–(BUSINESS WIRE)–#DEL–BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library (DEL) technology services in China to help more innovative pharmaceutical companies quickly discover small molecule drugs. X-Chem will leverage its … [Read more…]

Drug Pricing Bill Caps Years of AHF Advocacy

Major Defeat for Big Pharma LOS ANGELES–(BUSINESS WIRE)–AIDS Healthcare Foundation welcomes the U.S. Senate’s vote to approve historic legislation empowering Medicare to lower drug prices. “I particularly want to thank President Biden. In his persistent and dogged determination, the president didn’t give up. He prodded, cajoled and pushed his former Senate colleagues to bring home … [Read more…]

Biocom California Statement on New Drug Pricing Legislation

SOUTH SAN FRANCISCO, LOS ANGELES, SAN DIEGO & WASHINGTON–(BUSINESS WIRE)–Biocom California, the association representing the life science industry of California, issued the following statement regarding the drug pricing portion in the Inflation Reduction Act. The statement can be attributed to Joe Panetta, Biocom California’s president and CEO: “After a detailed review and consideration of the … [Read more…]

BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022

BRANFORD, Conn. & NESS ZIONA, Israel–(BUSINESS WIRE)–BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 10, 2022, at 8:00 a.m. EDT, … [Read more…]

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer

Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or … [Read more…]

ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer

Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the … [Read more…]

U.S. FDA Approves Additional Indication of NUBEQA® (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NUBEQA now has indications in both metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)1 Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program was based on the pivotal Phase III ARASENS trial, which showed a significant overall survival (OS) benefit with NUBEQA plus androgen deprivation therapy (ADT) and docetaxel compared … [Read more…]

Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter’s Option to Purchase Additional Stock

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 2,012,500 shares of its common stock at a price of $63.85 per share to the underwriter, which includes the … [Read more…]